Daiichi Sankyo hones R&D focus on thrombosis and cancer
This article was originally published in Scrip
Following the recent EU approval and positive US recommendation for the platelet inhibitor Effient (prasugrel), Daiichi Sankyo is focusing attention on its next promising cardiovascular product, edoxaban (DU-176b).
You may also be interested in...
Partners say they are encouraged by new overall response data from early trials for the two drugs together in kidney and liver cancer, presented to ASCO.
Focused on precision medicine for renal disease, Chinook gets Aduro’s Nasdaq listing and starting capital of $200m. During a wave of modest-sized M&A deals, Tetra finds buyer, Tetraphase gets competing bids.
Takeda is confident about the promise of its first-in-class molecule for higher-risk myelodysplastic syndromes after positive Phase II data.